About bioLytical Laboratories

Slides:



Advertisements
Similar presentations
Nick Curry, MD, MPH Infectious Diseases Prevention Section
Advertisements

Implementing Rapid HIV Testing: Technologies, Legal and Cost Issues Vanessa Lee, MPH HIV Rapid Testing Coordinator CA Office of AIDS.
Rapid HIV Testing and Its Role in Advancing HIV Prevention: 2004 Update Bernard M. Branson, M.D. Chief, Lab Determinants and Diagnostics Section Centers.
Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.
Results of a Pilot Point-of-Care (POC) HIV Testing Program using INSTI HIV in an Urban Sexual Health Clinic in Canada Presentation to: 2007 HIV Diagnostics.
Pediatric Diagnosis of HIV-1 Infection Using Dried Blood Spots Chin-Yih Ou, PhD NCHSTP/DHAP Centers for Disease Control and Prevention.
Implementing screening for acute HIV infection in STD clinics already using rapid HIV antibody testing, New York City, 2007 Kathleen D. Gallagher, MPH.
HIV Diagnostics and A New Testing Algorithm
1 Quality System Considerations for Over-The-Counter HIV Testing Devery Howerton, Ph.D. Chief, Laboratory Practice Evaluation and Genomics Branch, Division.
MAJ Kris Paolino, MD Infectious Disease Staff Chief, Clinical Trials Center Walter Reed Army Institute of Research.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Primary HIV Infection: the CDC study Pragna Patel, MD MPH Medical Epidemiologist Behavioral and Clinical Surveillance Branch DHAP, CDC February 28, 2005.
Increasing Our Reach through Rapid HIV Testing Bernard M. Branson, M.D. Chief, Lab Determinants and Diagnostics Section Centers for Disease Control and.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Can a second rapid HIV test discriminate false positives as effectively as a Western Blot? The NJ Experience Evan M. Cadoff, MD Robert Wood Johnson Medical.
Alere TM HIV Combo Yuko Tamanoue, Product Development Department.
Preventing HIV/AIDS There is no way to tell just by looking whether a person is infected with HIV. Because people are unaware that they are HIV-positive,
HIV Testing CDC power point edited by M. Myers
HIV Screening and Women’s Health Health Care Education & Training, Inc. Originally developed by: Section 5: Test Options.
HIV Testing Quality Assurance and Quality Control
Rapid HIV Testing: 2003 Update Bernard M. Branson, M.D. Chief, Lab Determinants and Diagnostics Section Centers for Disease Control and Prevention.
Implementing Rapid HIV Testing in the United States Bernard M. Branson, M.D. Centers for Disease Control and Prevention Overview and Background.
Performance of rapid HIV tests used singly and in combination: Moving toward a point of care diagnosis. Kevin Delaney, MPH HIV Diagnostics: New Developments.
An Approach for a Rapid HIV Antibody Home-Use Oral Fluid Test 1 An Approach for a Rapid HIV Antibody Home-Use Oral Fluid Test OraSure Technologies, Inc.
HIV/AIDS is preventable and treatable, but is incurable.
1 OraQuick ® ADVANCE ™ HIV 1/2 Antibody Test (Oral Fluid Specimen Type) Blood Products Advisory Committee Meeting March 10, 2006.
RESULTS Rapid testing started at one publicly funded counseling and testing site in New Jersey on November 1, Through December 31, 2004, 48 sites.
HIV testing at the ICTC ICTC Team Training.
Trinity Biotech Fingerstick whole blood sample for HIV OTC test Presented by; Fiona Campbell.
1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIVAIDS, Viral Hepatitis, STD,
HIV/AIDS is preventable and treatable, but is incurable.
CLIA Waiver for the OraQuick ® Rapid HIV-1 Antibody Test Elliot P. Cowan, Ph.D. Senior Regulatory Scientist Office of Blood Research and Review Center.
RAPID HIV TESTING OraQuick ADVANCE HIV 1/2
BioPlex 2200 HIV Ag-Ab Assay
© Coherent market Insights. All Rights Reserved PEDIATRIC CLINICAL TRIALS MARKET Global Industry Insights, Outlook Size, Share and Opportunity Analysis,
Alere HIV Diagnostic Care; Solutions to Fast Track
Matilu Mwau, M.D., MTM, D.Phil(Oxon)
TUPEB018 Field evaluation of rapid HIV serologic tests for screening HIV-1/2 infection using serum samples from Rakai Cohort, Uganda. S.C. Kagulire, P.D.
LAM assay: overview and practical guidance on its adoption and use
California Clinical Laboratory Association
Laboratory Diagnosis of Infectious Diseases
In the Footsteps of the WHO – Rapid HIV Testing in America
Nucleic Acid Amplification Test for Tuberculosis
Global HIV Diagnosis Market to Witness 10.6% CAGR during 2017 – 2023.
Opportunity Analysis and Industry Forecast, HIV Diagnosis MarketHIV Diagnosis Market Top Key Players, Trends, Share to 2023tein Market.
Unigold Recombigen HIV 1/2 Training for HIV Testing Sites
Acute HIV Infection and PrEP: Opportunities and challenges
Content and Labeling of Tests Marketed as Clinical “Whole-Exome Sequencing” Perspectives from a cancer genetics clinician and clinical lab director Allen.
San Francisco Department of Public Health
INTEGRATING HIV AND HCV TESTING.
BBI Detection - IMASS Training
Databridgemarketresearch.comdatabridgemarketresearch.com US : UK :
Quality System Considerations for Over-The-Counter HIV Testing
Sarah E. Rutstein, MD, PhD University of North Carolina at Chapel Hill
NUCLEIC ACID AMPLIFICATION TESTING DETECTS HIV TRANSMISSION RISK IN SEROLOGICALLY- TESTED BLOOD DONOR UNITS. |Presented by Miss Shemau Muniru| Authors:
Quality Control Barbara Weberman MT(ASCP)
AIDS in the United States
1985: First HIV-1 ELISA Approved by FDA
A CASE SERIES OF DISCORDANT LABORATORY RESULTS WITH RAPID HIV TESTING
Role of KMLTTB in HIV POC implementation
Rapid-Rapid Point of Care Testing
Performing Sedia Asante: Testing algorithm
HIV-1 Rapid Test for Recent Infection
TRACE INITIATIVE: Overview
Performing Maxim Swift RIA: Testing algorithm
Share your thoughts on this presentation with #IAS2019
HIV-1 Rapid Test for Recent Infection
Presentation transcript:

FDA Approved, CLIA-Waived Rapid HIV Test, Results in as Little as 60 Seconds.

About bioLytical Laboratories bioLytical Laboratories is located in Richmond BC, Canada. Privately owned, federally incorporated Canadian company. Leading developer of rapid diagnostic assays. Exclusive manufacturer of the INSTI® HIV-1/HIV-2 Antibody Test. US TRAINING PRESENTATION

Research & Development bioLytical R&D recently built a pre-clinical prototype for a 60-second Ebola antigen test and are currently developing various Class 1-3 individual and multiplex assays, all on the proven, 60 second INSTI’s platform. bioLytical’s 60 Second Ebola Test announcement in Times Square, NYC. US TRAINING PRESENTATION

INSTI HIV Health Canada Regulatory Approvals 2006 2010 2012 2014 2015 INSTI HIV Health Canada Approved & CE Marked INSTI HIV FDA Approved INSTI HIV FDA CLIA Waived INSTI HIV WHO Pre- qualified INSTI Multiplex CE Marked Approved for sale in more than 58 countries in Europe, North America, Africa, Middle East, Latin America and Asia Approved for USAID / PEPFAR Waiver List World Health Organization pre-qualified ISO 13485 Accredited facility US TRAINING PRESENTATION

Global HIV/AIDS Strategy By 2020 US TRAINING PRESENTATION

Why INSTI? US TRAINING PRESENTATION

1. Instant Results INSTI uses flow-through technology: Reagents are added to the membrane unit well and flow down into an absorbent pad for results in as little as 60 seconds. Most diagnostic assays are lateral flow, meaning fluid has to flow laterally or across to generate a result – usually in the form of one or two lines over 10 - 40 minutes. US TRAINING PRESENTATION

2. Accuracy INSTI is over 99% accurate. Sample Sensitivity Specificity Fingerstick Blood (FSB) 99.8% 99.5% EDTA Whole Blood 99.9% 100% Plasma CLIA Fingerstick Blood* Sensitivity (also called the true positive rate) measures the proportion of actual positives which are correctly identified as such (e.g., the percentage of sick people who are correctly identified as having the condition), and is complementary to the false negative rate. Specificity (sometimes called the true negative rate) measures the proportion of negatives which are correctly identified as such (e.g., the percentage of healthy people who are correctly identified as not having the condition). Source: INSTI HIV-1/HIV-2 Antibody Test Package Insert *Galli RA, Green KF, La Marca A, et al. Evaluation of the accuracy and ease of use of a rapid HIV-1 Antibody Test performed by untrained operators at the point of care. J Clin Virol 2013;58 Suppl I:e65-9. US TRAINING PRESENTATION

3. Sensitivity US CDC data shows INSTI as the most sensitive CLIA-waived antibody test, detecting HIV infection 9 days earlier than Western Blot. For Determine, demonstrating sensitivity of Antibody component. Window Period: while INSTI can at times produce a reactive result as early as a few weeks after infection, the window period for RULING OUT HIV infection, i.e. with a negative INSTI result, remains 12 weeks. This is the same window period for all HIV antibody tests, whether in the lab or point of care. US TRAINING PRESENTATION

3. Sensitivity Virological and serological markers of HIV-1 infection Window Period: while INSTI can at times produce a reactive result as early as a few weeks after infection, the window period for RULING OUT HIV infection, i.e. with a negative INSTI result, remains 12 weeks. This is the same window period for all HIV antibody tests, whether in the lab or point of care. US TRAINING PRESENTATION

Center for Disease Control, Source Data Legend: Dark blue (Aptima), RNA Nucleic Acid Amplified Test or NAAT ; Green (Architect, Bio-Rad, and the POC Determine), 4th generation assays detection of antibody and antigen; Blue (Advia, Vitros, GS), laboratory-based antibody detection assays; Pink (INSTI, Multi-Spot, Reveal), flow-through antibody detection assays; Purple (Complete, Stat-Pack, Unigold, OraQuick), rapid Antibody detection assays; Blue (Western Blot), lab-based antibody-detection assay, Brown (Vironostka), lab-based antibody detection assay. CLIA-waived: INSTI (bioLytical), Determine 4G (Alere), Clearview Complete (Alere), Stat-Pack (Chembio), Unigold (Trinity Biotech), OraQuick (OraSure). Recently CLIA-waived, not pictured: DPP (Chembio). US TRAINING PRESENTATION

4. Ease of Use Sample, Pour, Interpret Results Immediately! *All sample collection materials provided (lancet, pipet and alcohol swab.) US TRAINING PRESENTATION

5. Clear, Stable Results US TRAINING PRESENTATION

What is the Significance of a 60 Second Screening Tool? US TRAINING PRESENTATION

Never miss an opportunity to test! INSTI’s 60-Second platform creates greater flexibility for POC healthcare, removing barriers to testing, increasing access to care and empowering testers to adapt to patients’ needs. Never miss an opportunity to test! US TRAINING PRESENTATION

in innovative settings. In Other Words, INSTI: Improves efficiency in traditional healthcare settings, & Creates new opportunities to test in innovative settings. US TRAINING PRESENTATION

1 Minute Models: Real INSTI Users Pharmacy Pre-natal care Emergency Room Pre-natal care AIDS Service Organisation Correctional Facilities Mobile/ Outreach Pharmacy US TRAINING PRESENTATION

Format INSTI (Available in Boxes of 50) Instructions for Use 1 membrane unit 3 reagent solutions Sample collection materials Lancet, pipette, alcohol swab Note: INSTI 24s have been discontinued. US TRAINING PRESENTATION

Contract #: MG01099 US TRAINING PRESENTATION

“Got a Minute?” Feedback & Testimonials “This test is a game-changer and will lead to new ways of reaching people.” -Senior Director of Public Health (AHF) Survey Feedback from bioLytical’s National HIV Testing Day 2014 Campaign: This was the most successful National HIV Testing Day that we have ever had based on the numbers tested and number of target population tested. I love INSTI tests... I would love to use theses tests in the future The product is amazing, the ease of use, accuracy and speed was such a convenient feature for the patient and the tester. I would definitely recommend your product!!! Just started using INSTI and it makes a lot of sense. The earlier detection and the speed offering clients results is a plus. Great test, really easy to use and rapid results. Only test we use during street outreach activities…” US TRAINING PRESENTATION

Contacts: US TRAINING PRESENTATION

Thank You! One minute can change the world. It starts with a test; it start with you. US TRAINING PRESENTATION